From the Journals

Obesity is linked to some RCC subtypes


 

FROM CANCER EPIDEMIOLOGY

The link between obesity and renal cell carcinoma (RCC) appears to be complex and may provide insight into differing etiologies for various histologic subtypes of this cancer, according to a nested case-control study and subsequent meta-analysis.

Investigators led by Catherine L. Callahan, PhD, a postdoctoral fellow with the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Md., first analyzed data from the Kaiser Permanente Northern California health care network. They matched 685 patients with RCC (421 clear cell, 65 papillary, 24 chromophobe, 35 other, and 140 not otherwise specified) with 4,266 unaffected control patients on age, sex, race/ethnicity, duration of network membership, and medical center of diagnosis.

Compared with normal-weight counterparts (body mass index less than 25 kg/m2), obese patients (body mass index of at least 30 kg/m2), had a significantly elevated risk of clear cell RCC (odds ratio, 1.5) and a nonsignificantly elevated risk of chromophobe RCC (2.5), but a similar risk of papillary RCC (1.0), according to results reported in Cancer Epidemiology. Associations weakened when cases were restricted to stage II or higher RCC, suggesting potential bias from incidental diagnoses related to abdominal imaging. Patients who were overweight (body mass index of 25 to 29.9 kg/m2) did not have significantly elevated risks of any subtype of RCC.

The investigators next conducted a meta-analysis, including this new study and three others. Results showed a significant link between obesity and clear cell RCC (summary relative risk, 1.8) and chromophobe RCC (2.2), but not papillary RCC (1.2). Here, however, patients who were overweight also had elevated risks of clear cell RCC (1.3) and chromophobe RCC (1.9).

“Our results provide support for the hypothesis that histologic subtypes of RCC represent distinct etiologic pathways, and that obesity is more strongly associated with risk of clear cell RCC. Additional research to elucidate the underlying biology of specific subtypes of RCC is warranted,” wrote Dr. Callahan and her coinvestigators. “More generally, our findings underscore the importance of accounting for histologic subtype in investigations of RCC etiology.”

The investigators disclosed that they had no conflicts of interest. The research was supported by the Intramural Research Program of the NIH and the National Cancer Institute.

SOURCE: Callahan CL et al. Cancer Epidemiol. 2018 Jul 18, doi: 10.1016/j.canep.2018.07.002.

Recommended Reading

PD1 mRNA may predict response to anti-PD1 monotherapy across cancer types
MDedge Hematology and Oncology
Prognostic model has clinical utility in mCRPC
MDedge Hematology and Oncology
Osteonecrosis of jaw in mRCC higher with denosumab/antiangiogenics
MDedge Hematology and Oncology
TKIs feasible and effective in Brazilian population with clear cell RCC
MDedge Hematology and Oncology
SBRT controls oligometastatic RCC in majority of patients
MDedge Hematology and Oncology
CRP levels may augur RCC prognosis
MDedge Hematology and Oncology
Partial nephrectomies on rise for early-stage RCC
MDedge Hematology and Oncology
For solitary renal tumors, RFA looks good at 10 years
MDedge Hematology and Oncology
Pazopanib is active against renal, other neoplasms of von Hippel-Lindau disease
MDedge Hematology and Oncology
Better therapy, not earlier diagnosis, explains improved RCC survival
MDedge Hematology and Oncology